Improved glycaemic control and weight benefit with <scp>iGlarLixi</scp> versus insulin glargine 100 U/ <scp>mL</scp> in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the <scp>LixiLan‐L‐CN</scp> randomized controlled trial-Reference-Cited by-同舟云学术

Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/ mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial

Published:2022-07-25 Issue:11 Volume:24 Page:2182-2191
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Yuan Xiaoyong¹,Guo Xiaohui¹,Zhang Junqing¹,Dong Xiaolin²,Lu Yibing³,Pang Wuyan⁴,Gu Shenghong⁵,Niemoeller Elisabeth⁶,Ping Lin⁷,Nian Gaowei⁸,Souhami Elisabeth⁹,

Affiliation:

1. Peking University First Hospital Beijing China

2. Jinan Central Hospital Jinan China

3. The Second Affiliated Hospital of Nanjing Medical University Nanjing China

4. Huaihe Hospital of Henan University Kaifeng China

5. Sanofi Shanghai China

6. Sanofi Frankfurt Germany

7. Sanofi Bridgewater NJ USA

8. Sanofi Beijing China

9. Sanofi Paris France

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14803

Reference29 articles.

1. International Diabetes Federation.IDF Diabetes Atlas – Tenth Edition.2021;https://diabetesatlas.org/. Accessed December 15 2021.

2. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China

3. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition);Chinese Diabetes Society;Chin J Diabetes Mellitus,2020

4. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

5. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial;Diabetes, Obesity and Metabolism;2024-08-19

2. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial;Diabetes, Obesity and Metabolism;2024-06-22

3. IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective;Journal of Basic and Clinical Physiology and Pharmacology;2024-06-11

4. iGlarLixi for type 2 diabetes: a systematic review and meta-analysis;Endocrine;2024-05-13

5. Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review;BMJ Open Diabetes Research & Care;2024-05